Clinical Trial Update: TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial results comparing rilpivirine (TMC278) to efavirenz, both with two nucleoside reverse transcriptase inhibitors, in treatment-naive HIV-1 patients.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)
• Sustiva (efavirenz)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections, HIV-1 | Phase 3 | Status: COMPLETED | Results posted: 2011-07-12